Gedeon Richter Plc. updates patient information for Vermox medication

Gedeon Richter Plc., a pharmaceutical company, has issued updated patient information for its product Vermox, 100 mg tablets. The active ingredient in Vermox is mebendazole, which belongs to the benzimidazole class of antihelminthic agents used to treat infections caused by various types of parasites.

The updated leaflet outlines crucial usage instructions and contraindications. Vermox should not be administered to children under 3 years of age, during pregnancy, or in individuals with inflammatory bowel conditions such as ulcerative colitis or Crohn's disease, or liver insufficiency. Hypersensitivity to mebendazole or any other components of the tablet is also listed as a contraindication.

Patients with diabetes mellitus are advised that the medication may affect blood sugar levels and potentially reduce insulin requirements. Concomitant use of mebendazole with metronidazole should be avoided due to the risk of severe adverse reactions. Long-term treatment may necessitate periodic blood tests. The leaflet also warns that the medication can cause dizziness and drowsiness, advising caution when driving or operating machinery.